Christopher J O'Callaghan
机构: Canadian Cancer Trials Group, Cancer Research Institute, Queen's University
主页: queensu.ca
每年引用次数
引用次数
引用: 12,491
H-指数: 44
I10-指数 : 70
出版物: 132
A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme
M Fay , R Nishikawa , Johan Menten , C. J O'Callaghan
Neuro-oncology 12 38 -38
24
2010
Scarring in molluscum contagiosum: comparison of physical expression and phenol ablation
R. Weller , C. J O'Callaghan , R. M MacSween , M. I White
BMJ 319 ( 7224) 1540 -1540
29
1999
Canadian nurses' and respiratory therapists' perspectives on withdrawal of life support in the intensive care unit
Graeme M. Rocker , Deborah J. Cook , Christopher J. O'Callaghan, , Deborah Pichora
Journal of Critical Care 20 ( 1) 59 -65
33
2005
Randomised Phase 3 Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) - INTEGRATE II
Yu Jo Chua , Nick Pavlakis , Katrin M. Sjoquist , Andrew J. Martin
Annals of Oncology 30 vi137
2019
First evidence of bluetongue virus in Kazakhstan.
M Lundervold , EJ Milner-Gulland , CJ O’callaghan , C Hamblin
Veterinary Microbiology 92 ( 3) 281 -287
45
2003
Field research project to assess health and production indices on Kenyan smallholder dairy farms
JJ McDermott , GK Gitau , CJ O’callaghan , AO Omore
Livestock Services for Smallholders, Proceedings of an International Seminar held in Yogyakarta, Yogyakarta 77 -80
4
1992
Field research project to assess health and production indices on Kenyan smallholder dairy farms
Julius K Kilungo , JJ McDermott , GK Gitau , CJ O’callaghan
2015
A study of the epidemiology of theileriosis on smallholder dairy farms in Kiambu District, Kenya.
Christopher John O'Callaghan
0527 -0527
20
2000
stroma) of Apodemus spp.
CJ O'CALLAGHAN
Parasitology 118 425 -432
17
1999
Investigating the epidemiology of heartwater (Cowdria ruminantium infection) by means of a transmission dynamics model
CJ O'CALLAGHAN , GF Medley , TF Peter , Brian D Perry
Parasitology 117 ( 1) 49 -61
61
1998
Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).
Di Maria Jiang , Hao-Wen Sim , Lillian L Siu , Jeremy David Shapiro
Journal of Clinical Oncology 35 699 -699
2017
Hypertension and beta-blocker use as prognostic and predictive factors in metastatic colorectal cancer: A retrospective analysis of NCIC CTG CO.17.
Shelly Sud , Christopher J O'Callaghan , Christos Stelios Karapetis , Caleb Jonker
Journal of Clinical Oncology 34
2016
The CCTG CO.26 trial: A phase II randomized study of durvalumab plustremelimumab and best supportive care (BSC) vs BSC alone in patients with advanced colorectal carcinoma (CRC) refractory to standard therapies.
Eric Xueyu Chen , Derek J. Jonker , Hagen F. Kennecke , Sheryl L. Koski
Journal of Clinical Oncology 35
4
2017
The CCTG PA.7 trial: A randomized phase II study of gemcitabine and nab-paclitaxel vs. gemcitabine, nab-paclitaxel, durvalumab, and tremelimumab as 1st line therapy in metastatic pancreatic ductal adenocarcinoma (PDAC).
Daniel John Renouf , Petr Kavan , Neesha C Dhani , Derek J Jonker
Journal of Clinical Oncology 35
1
2017
Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)—An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).
Katrin Marie Sjoquist , Nick Pavlakis , Andrew James Martin , Eric Tsobanis
Journal of Clinical Oncology 35
8
2017
Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.
Jolie Ringash , Heather-Jane Au , Lillian L. Siu , Jeremy D. Shapiro
Cancer 120 ( 2) 181 -189
14
2014
End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group
Daniel J. Sargent , Smitha Patiyil , Greg Yothers , Daniel G. Haller
Journal of Clinical Oncology 25 ( 29) 4569 -4574
191
2007
Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17.
Stephanie Yasmin Brule , Derek J. Jonker , Christos Stelios Karapetis , Christopher J. O'Callaghan
Journal of Clinical Oncology 31 3528 -3528
19
2013
Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.
Michael M. Vickers , Dongsheng Tu , Chee Lee , Paul Wheatley-Price
Journal of Clinical Oncology 31 4053 -4053
1
2013
Comparative efficacy of local versus systemic salvage therapies for recurrent prostate cancer after primary radiotherapy.
Glenn Bauman , Keyue Ding , Joseph Chin , Alessandra Iaboni
Journal of Clinical Oncology 38 221 -221
2020